Balanced news tone
News Sentiment
ABBV sentiment intelligence
AbbVie Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
60
Balanced news tone
29 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
+1.5% over one week, +7.7% over four weeks, trend inactive, and near fair-value range.
AbbVie (ABBV) Wins FDA Nod For SKINVIVE While CLL Trial Data Strengthens Pipeline
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
1.5%
Price digesting
Trend fit
Trend inactive
7.7% over four weeks
Fair value
15.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
18
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Direct company coverage
AbbVie (ABBV) Wins FDA Nod For SKINVIVE While CLL Trial Data Strengthens Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 03:55
- Source
- simplywall.st
Market source
Direct company coverage
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Jun 2026 21:45
- Source
- Market source
Market source
Direct company coverage
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 13:00
- Source
- Market source
GuruFocus
Direct company coverage
AbbVie Inc (ABBV) Stock Price, Trades & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 12:13
- Source
- GuruFocus
Seeking Alpha
Direct company coverage
AbbVie: Maintaining My Strong Buy Rating After Label Expansion (NYSE:ABBV)
- Tone
- Positive 95/100
- Event
- Analyst action
- Published
- 16 Jun 2026 21:31
- Source
- Seeking Alpha
24/7 Wall St.
Direct company coverage
AbbVie Stock Will Hit $300 on This Date
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 17:30
- Source
- 24/7 Wall St.
simplywall.st
Direct company coverage
AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 10:31
- Source
- simplywall.st
TIKR.com
Direct company coverage
AbbVie Stock in 2026: Skyrizi and Rinvoq Drive 12% Revenue Growth as Margins Begin to Inflect
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 15 Jun 2026 16:15
- Source
- TIKR.com
simplywall.st
Direct company coverage
AbbVie (ABBV) Stock After Steady Gains Can DCF Upside Offset A Lofty P/E Ratio
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 13 Jun 2026 14:23
- Source
- simplywall.st
Market source
Direct company coverage
AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jun 2026 14:09
- Source
- Market source
Market source
Direct company coverage
Is AbbVie Inc. (ABBV) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Jun 2026 18:00
- Source
- Market source
Market source
Direct company coverage
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Market source
TIKR.com
Direct company coverage
AbbVie Stock: The Post-Humira Transition Is Working and the Road to $311
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 May 2026 07:00
- Source
- TIKR.com
Market source
Direct company coverage
AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Market source
IndexBox
Direct company coverage
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026 - News and Statistics
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 24 Apr 2026 07:00
- Source
- IndexBox
Market source
Direct company coverage
AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Market source
IndexBox
Direct company coverage
AbbVie Stock Review 2026: Earnings Outlook, Dividend Yield, and Valuation - News and Statistics
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Apr 2026 07:00
- Source
- IndexBox
Market source
Direct company coverage
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Top Stock Reports for AbbVie, Coca-Cola & Chevron
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Dec 2025 08:00
- Source
- Market source
PR Newswire
Direct company coverage
AbbVie Reports Third-Quarter 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 31 Oct 2025 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
AbbVie Declares Quarterly Dividend
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 05 Sep 2025 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
AbbVie Reports Second-Quarter 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 31 Jul 2025 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
AbbVie Reports First-Quarter 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2025 07:00
- Source
- PR Newswire
Market source
Direct company coverage
Jim Cramer Says AbbVie Inc. (ABBV) Is A ‘Buy’
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Feb 2025 08:00
- Source
- Market source
Market source
Direct company coverage
AbbVie (NYSE:ABBV) Has A Pretty Healthy Balance Sheet
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2025 08:00
- Source
- Market source
PR Newswire
Direct company coverage
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2024 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
AbbVie to Acquire Allergan in Transformative Move for Both Companies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2019 07:00
- Source
- PR Newswire
Forbes
Direct company coverage
AbbVie
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jul 2016 09:43
- Source
- Forbes